Leukemia, Myelodysplasia, Transplantation
Clinical Insights
COVID-19 prompts ‘democratization’ of cancer trials
Dr. Alan Lyss reviews a panel discussion about how COVID-19 has affected cancer research.
Conference Coverage
HMAs plus novel agents may improve outcomes in higher-risk MDS
Conference Coverage
TKI choice key for fit/unfit patients with Ph+ALL
Ponatinib (Iclusig) is associated with high response rates in combination therapy, but toxicities may be too great for less fit patients.
Conference Coverage
For lower-risk MDS, treat ‘what bugs patients most’
From the Journals
Oxidative stress linked to cytogenetic abnormalities in CLL
From the Journals
CSF metabolomic profile linked to cancer-related fatigue in children with ALL
From the Journals
Hair dye and cancer study ‘offers some reassurance’
News
FDA approves first maintenance therapy for AML
Conference Coverage
VTE, sepsis risk increased among COVID-19 patients with cancer
Cancer patients had significantly lower hemoglobin levels, platelet counts, and red and white blood cell counts.
From the Journals
Aspirin may accelerate cancer progression in older adults
From the Journals
Antihistamines synergistically induce CLL cell death with TK inhibitors
Over-the-counter antihistamines induced synergistic cytotoxicity with TK inhibitors.